title: Pathophysiology of lymphedema-Is there a chance for medication treatment?
abstract: Lymphedema is a common morbid after cancer treatment. The disease characterizes with progressive inflammatory process that result in irreversible fibrosis. Its chronology and progressive disease character often impacts the quality of life of cancer survivors. The pathophysiology of lymphedema remains unclear and the disease remains non-curable. In this article, we reviewed available studies of lymphedema and concluded possible treatment strategies for lymphedema. J. Surg. Oncol. 2017;115:96-98. © 2016 Wiley Periodicals, Inc.
authors: Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
authors: Geoffrey E
authors: GE
authors: Hespe
authors: Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
authors: Gabriela Garcia
authors: GG
authors: Nores
authors: Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.|Division of Reconstructive Microsurgery, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.|Center of the Tissue Engineering, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
authors: Jung-Ju
authors: JJ
authors: Huang
authors: Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
authors: Babak J
authors: BJ
authors: Mehrara
mesh_terms: D000818:Animals; D006801:Humans; D008209:Lymphedema / Q000188:drug therapy* / Q000503:physiopathology*
keywords: T-cell; inflammation; lymphedema